KTTAW news & sentiment — Pasithea Therapeutics Corp.

SEP 8·BenzingaMed

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee ( SRC ) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Pasithea Therapeutics ( NASDAQ:KTTA ) , Pasithea Therapeutics ( NASDAQ:KTTAW )

-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.

AUG 29·Benzinga

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics ( NASDAQ:KTTA ) , Pasithea Therapeutics ( NASDAQ:KTTAW )

MIAMI, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. KTTA ( "Pasithea" or the "Company" ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management's live presentation at the ...

MAY 7·Benzinga

Pasithea Therapeutics Announces Closing of $5 Million Public Offering - Pasithea Therapeutics ( NASDAQ:KTTA ) , Pasithea Therapeutics ( NASDAQ:KTTAW )

MIAMI, May 07, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics, Corp. ( "Pasithea," or the "Company" ) KTTA KTTAW ) ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 ( NF1 ) and other cancer ...

$KTTAW

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee ( SRC ) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Pasithea Therapeutics ( NASDAQ:KTTA ) , Pasithea Therapeutics ( NASDAQ:KTTAW )

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics ( NASDAQ:KTTA ) , Pasithea Therapeutics ( NASDAQ:KTTAW )

Pasithea Therapeutics Announces Closing of $5 Million Public Offering - Pasithea Therapeutics ( NASDAQ:KTTA ) , Pasithea Therapeutics ( NASDAQ:KTTAW )

News on $KTTAW